• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Trial Registries Don’t Include All Side Effects, Study Shows

Clinical Trial Registries Don’t Include All Side Effects, Study Shows

April 19, 2021

Clinical trial registries, such as ClinicalTrials.gov, include less information on harmful side effects than the clinical study reports submitted to regulators as part of new drug applications, according to a new study that urges regulators to make the reports public.

Researchers from the University of Southern Denmark and the University of Paris looked at 42 trials evaluating 13 cancer drugs whose makers were seeking approval from the European Medicines Agency between 2015 and 2018. The researchers then scrutinized data available on side effects caused by the 13 drugs.

The number of deaths caused by adverse events differed between clinical study reports and clinical trial registries in 92 percent of trials, and with journal articles in 40 percent of trials, the researchers say in an article published in the journal BMC Medicine. And the number of deaths due to adverse events was not available at all in ClinicalTrials.gov.

Also, the number of patients with at least one serious adverse event was reported in only half of published journal articles, according to the study.

Additionally, the number of patients stopping treatment with a drug because of adverse events was different in clinical study reports and clinical trial registries for 88 percent of trials that included such information in both sources.

The researchers also found that information about clinical trials was hard to obtain, taking more than two years on average after the end of a trial until results were published in academic journals and more than four years until the reports themselves were made available to the public.

“We consider it vital that regulators start routinely releasing case study reports,” the researchers wrote.

In 2018, the FDA began a voluntary pilot program to examine the possibility of sharing clinical study reports, but it stalled as companies didn’t respond to the agency’s requests for participation. Last year, FDA stopped the program, saying it would seek to harmonize such efforts at transparency with regulatory bodies in other countries.

At the time, FDA said such harmonization could include a centralized international library managed by an independent organization. The agency added that participation would be voluntary.

Read the full BMC Medicine report here: https://bit.ly/3uK54LD.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing